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TRAIL regulatory receptors 
constrain human hepatic stellate 
cell apoptosis
Harsimran D. Singh1,2, Itziar Otano  1, Krista Rombouts2, Kasha P. Singh1,4, Dimitra Peppa1, 
Upkar S. Gill6, Katrin Böttcher2, Patrick T. F. Kennedy6, Jude Oben2,5, Massimo Pinzani2, 
Henning Walczak3, Giuseppe Fusai2, William M. C. Rosenberg2 & Mala K. Maini1
The TRAIL pathway can mediate apoptosis of hepatic stellate cells to promote the resolution of liver 
fibrosis. However, TRAIL has the capacity to bind to regulatory receptors in addition to death-inducing 
receptors; their differential roles in liver fibrosis have not been investigated. Here we have dissected the 
contribution of regulatory TRAIL receptors to apoptosis resistance in primary human hepatic stellate 
cells (hHSC). hHSC isolated from healthy margins of liver resections from different donors expressed 
variable levels of TRAIL-R2/3/4 (but negligible TRAIL-R1) ex vivo and after activation. The apoptotic 
potential of TRAIL-R2 on hHSC was confirmed by lentiviral-mediated knockdown. A functional 
inhibitory role for TRAIL-R3/4 was revealed by shRNA knockdown and mAb blockade, showing that 
these regulatory receptors limit apoptosis of hHSC in response to both oligomerised TRAIL and NK cells. 
A close inverse ex vivo correlation between hHSC TRAIL-R4 expression and susceptibility to apoptosis 
underscored its central regulatory role. Our data provide the first demonstration of non-redundant 
functional roles for the regulatory TRAIL receptors (TRAIL-R3/4) in a physiological setting. The potential 
for these inhibitory TRAIL receptors to protect hHSC from apoptosis opens new avenues for prognostic 
and therapeutic approaches to the management of liver fibrosis.
Chronic liver inflammation and injury from a variety of insults trigger a dynamic, reversible wound-healing 
response, in which matrix deposition is accompanied by matrix degradation. If there is chronic or repetitive 
injury, persistent accumulation of extracellular matrix and insufficient tissue remodelling lead to the formation 
of scar tissue1. The resultant liver fibrosis can ultimately lead to cirrhosis, portal hypertension and liver failure, 
responsible for more than a million deaths annually worldwide2. Targeted therapies able to specifically halt the 
progression and/or promote regression of liver fibrosis are therefore urgently needed.
Hepatic stellate cells (HSC), liver-specific pericytes residing in the Space of Disse, are the main cellular medi-
ators of fibrogenesis in the liver1, 3, 4. In the quiescent state they contain multiple retinoid-rich droplets; upon liver 
injury they are activated to differentiate into proliferative and contractile myofibroblast-like cells, that produce 
the extracellular matrix components of scar tissue3. Termination of their pro-fibrogenic activity requires that HSC 
undergo apoptosis, senescence or reversion to a quiescent state4, 5. Degradation of extracellular matrix will then 
outweigh new deposition, allowing fibrosis resolution and restoration of liver architecture4, 5.
It is increasingly recognised that many different components of the immune system have the capability to either 
promote or limit HSC activation and survival3, 6, 7. Amongst these, NK cells are of particular interest because of 
their striking enrichment within the human liver, including a large CXCR6+TbethiEomeslo liver-resident subset8. 
In animal models, depletion of NK cells results in severely accelerated fibrosis progression whereas their acti-
vation ameliorates it9–11, suggesting that they play a major role in limiting fibrogenesis. NK cells can interact 
with HSC through a number of receptor/ligand pairs and have been shown to be able to kill them in an NKG2D 
and TRAIL-dependent manner10, 12–14. We have previously shown activation of the TRAIL pathway in the 
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HBV-infected liver; the ligand is induced on NK cells, allowing them to target hepatocytes and HBV-specific T 
cells, both of which upregulate the death-inducing receptor TRAIL-R215–17.
In this work we have therefore focused on the potential for the TRAIL pathway to regulate stellate cell 
apoptosis. The ligand TRAIL has the capacity to initiate cell death by engagement with receptors TRAIL-R1 
and TRAIL-R2, bearing intracellular death domains18–21. However, TRAIL can also bind to regulatory (decoy) 
cell-bound receptors TRAIL-R3 (DcR1) or TRAIL-4 (DcR2) that may protect against cell death, although to date 
there has been a scarcity of physiological demonstrations of this phenomena (demonstrable in over-expression 
systems18, 22–25). We have confirmed TRAIL-dependent killing of primary human HSC (hHSC) by using 
lentiviral-mediated shRNA knockdown of the death-inducing receptor TRAIL-R2. We found that hHSC also 
express TRAIL-R3 and TRAIL-R4, both directly ex vivo and after activation. Importantly, we show that knock-
down or blockade of these regulatory receptors enhances the susceptibility of hHSC to killing by oligomerised 
TRAIL and by TRAIL-expressing NK cells from patients with chronic hepatitis B (CHB). The baseline level of 
expression of the regulatory receptor TRAIL-R4 dictates the wide variability in susceptibility to TRAIL-induced 
apoptosis amongst hHSC from different donors, suggesting a role for regulatory TRAIL-Rs in limiting the reso-
lution of liver fibrosis.
Results
Primary human hepatic stellate cells express a functional death receptor for TRAIL. Primary 
hHSC were isolated from the healthy margins of liver resections carried out to remove colorectal cancer metas-
tases. After separation on a density gradient, hHSC were cultured and expanded for 2–5 passages to allow trans-
differentiation to activated myofibroblast-like cells. The cultured population was uniformly positive for the 
activated myofibroblast-specific marker anti-smooth muscle actin (αSMA, flow cytometric staining and RT-PCR, 
Supplementary Figure 1A,B). To investigate activated hHSC susceptibility to killing through engagement with the 
death ligand TRAIL, cells were stained and analysed by flow cytometry for TRAIL-Rs bearing intracellular death 
domains able to trigger cell death. Activated hHSC from eight different donors all expressed high levels of the 
TRAIL death receptor TRAIL-R2, as did the human stellate cell line LX2 (example histograms Fig. 1a, summary 
data Fig. 1b). By contrast, the alternative death-inducing receptor TRAIL-R1, detected at a much lower level than 
TRAIL-R2 by RT-PCR and immunoblot of activated hHSC and LX2 in previous studies13, 26, was not detectable 
above isotype staining using flow cytometry (Fig. 1a,b).
To test whether TRAIL-R2 played a functional role on hHSC, we developed shRNA for its selective knock-
down. A very high percentage of transduction of hHSC was achieved with lentiviral vectors (mean 90%), as 
monitored by their expression of GFP (representative example in Fig. 1c). Whilst hHSC transduced with a 
lentiviral-GFP with an irrelevant shRNA (shCTR) maintained high expression of TRAIL-R2, hHSC transduced 
with a GFP-expressing lentivirus carrying a shRNA against TRAIL-R2 had significantly reduced mRNA expres-
sion and almost completely abrogated protein expression of this death receptor (Fig. 1c and Supplementary 
Figure 1C).
Primary hHSC were then treated with an oligomerized form of the death ligand TRAIL (SuperKiller TRAIL), 
to simulate the clustering of receptors achieved by cell-bound TRAIL27. Induction of stellate cell apoptosis, quan-
titated by flow cytometry using caspase-3, was compared in live GFP-positive cells transduced with either shCTR 
or shTRAIL-R2 (representative example, Fig. 1d). SuperKiller TRAIL induced a variable degree of apoptosis 
(mean 36%, range 2–61%) in transduced hHSC from different donors; this was consistently abrogated completely 
by TRAIL-R2 knockdown (Fig. 1e). These data demonstrated that TRAIL mediates apoptosis of hHSC through 
TRAIL-R2 and not TRAIL-R1.
Primary human hepatic stellate cells express the regulatory receptors TRAIL-R3 and TRAIL-R4 
directly ex vivo and upon activation. hHSC expressing TRAIL-R2 showed a wide-ranging suscep-
tibility to TRAIL-induced apoptosis, raising the possibility of counter-regulation. The receptors TRAIL-R3 
and TRAIL-R4 lack intracellular death domains and have been shown to play an inhibitory or decoy role after 
over-expression in cell lines18, 22–24, 28–31. We therefore extended our staining of hHSC (cultured as described 
above) to include TRAIL-R3 and TRAIL-R4. Activated hHSC not only expressed TRAIL-R2 but also had variable 
levels of TRAIL-R3 and TRAIL-R4 detectable on their surface (Fig. 2a). The LX2 cell line expressed TRAIL-R4 
but not TRAIL-R3 (Fig. 2a).
To determine whether the detection of regulatory receptors on hHSC was an effect of in vitro activation, we 
also stained freshly isolated hHSC for all four surface-expressed TRAIL-Rs. As there are no flow-based markers 
to identify quiescent HSC, we gated out all other potential parenchymal, non-parenchymal and leucocyte line-
ages in the liver; the residual quiescent HSC population was negative for αSMA, as expected (Fig. 2b). Direct ex 
vivo TRAIL-R staining was performed on hHSC isolated and stained as above from seven donor livers (Fig. 2c). 
Variable levels of expression of the four receptors were observed between different donor samples. TRAIL-R1 was 
expressed at negligible levels, as noted on cultured hHSC. By contrast, staining for TRAIL-R2, R3 and R4 showed 
clear populations detectable in ex vivo hHSC from several donors (Fig. 2c).
Regulatory receptors limit TRAIL-dependent killing of activated hHSC. We next sought to deter-
mine whether the regulatory receptors TRAIL-R3 and TRAIL-R4 expressed on hHSC were capable of par-
tially inhibiting TRAIL-mediated apoptosis. To examine this, we developed shRNA to knockdown TRAIL-R3 
or TRAIL-R4. Partial or complete knockdown of these regulatory receptors was achieved following lentiviral 
transduction of hHSC from different donors with shRNA against TRAIL-R3 and of LX2 and hHSC with shRNA 
against TRAIL-R4, compared to lentiviruses with control shRNA (Fig. 3a,b). In every donor tested, knockdown 
of TRAIL-R3 or TRAIL-R4 resulted in enhanced hHSC apoptosis (measured by caspase-3 induction) upon treat-
ment with SuperKiller TRAIL (Fig. 3c,d).
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TRAIL regulatory receptors limit the capacity of NK cells to kill hHSC in CHB. To assess the role 
of regulatory receptors in stellate cell killing in response to a physiological rather than synthetic TRAIL ligand, 
we used NK cells from patients with CHB. We have previously found that NK cells from patients with CHB 
upregulate TRAIL on their surface and are able to kill hepatocytes and HBV-specific T cells through the TRAIL 
pathway15–17. NK cells from patients with hepatitis C have also been found to be able to kill hHSC in a partially 
TRAIL-dependent manner12. NK cells from our cohort of patients with CHB had increased TRAIL compared to 
healthy controls (Supplementary Figure 2A), in line with our previous studies15, 17. Purified NK cells were able to 
Figure 1. Expression of TRAIL-R2 on primary human HSC has pro-apoptotic function. (a) Representative 
FACS plots of expression level of pro-apoptotic TRAIL-R1 and TRAIL-R2 on hHSC (blue) against matched 
isotype control (grey). (b) Summary of expression levels of TRAIL-R1 and TRAIL-R2 on hHSC from 8 different 
donors (filled symbols) and LX2 (open symbols). (c) Representative FACS plot of levels of TRAIL-R2 at baseline 
(left), after lentiviral transduction (GFP + ) with shCTR (centre) and shTRAIL-R2 (right). (d) hHSC transduced 
with shCTR and shTRAIL-R2 were treated with SuperKiller TRAIL and the degree of apoptosis of transduced 
cells was assessed by gating on live GFP + cells that were positive for caspase-3. (e) Cumulative graph of 
apoptosis induction by SuperKiller TRAIL (% caspase3 + GFP + ) hHSC (filled) and LX2 (open circle) post-
knockdown of TRAIL-R2 (shTRAIL-R2) compared to control- short-hairpin RNA (shCTR) transduced hHSC. 
Baseline levels of caspase-3 post-transduction without addition of SuperKiller TRAIL were subtracted.
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induce variable, mostly limited, degrees of hHSC apoptosis (significantly above baseline apoptosis using NK cells 
from patients with CHB but not from healthy controls, Supplementary Figure 2B,C). The capacity of NK cells to 
induce hHSC apoptosis did not correlate with any parameters of CHB disease activity (viral load, ALT, fibrosis 
score, data not shown).
To investigate the role of regulatory TRAIL-Rs in limiting NK cell-mediated killing of hHSC, we took advan-
tage of blocking mAbs that allowed us to scale our assay up to test the large number of samples in our CHB 
cohort. TRAIL-R3 or TRAIL-R4 blockade or the combination were able to increase the capacity of NK cells to kill 
hHSC (example FACS plots, Fig. 4a). Using NK cells from a total of 27 patients with CHB, we compared blockade 
of TRAIL-R3, TRAIL-R4 and the combination (Fig. 4b), showing an enhancement of stellate cell apoptosis in 16 
out of 27 patients (59%) with one of more of these approaches. The limiting effects of TRAIL regulatory receptors 
on stellate cell killing by NK cells from different donors was only partially overlapping and they could therefore 
act in a complementary, and in some cases synergistic manner (Fig. 4b).
Taken together, these data indicated that blockade of the regulatory receptors TRAIL-R3/4 was able to 
enhance the induction of stellate cell apoptosis by oligomerised and cell-bound TRAIL ligand.
Figure 2. Expression of pro-apoptotic TRAIL-R2 and anti-apoptotic TRAIL-R3 and TRAIL-R4 on hHSC. 
(a) Percentage expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 on in vitro cultured hHSC 
(filled symbols) and LX2 (open symbols). (b) Gating strategy of freshly isolated primary human HSC. All 
other intrahepatic populations were sequentially gated out (CD19, cytokeratin, CD68, CD146, CD14, CD45, 
CD3, CD56 shown here excluded from pink gates, + /− CD45 not shown) to identify quiescent hHSC, then 
confirmed to be negative for αSMA (red line, final histogram). (c) ex vivo expression of TRAIL-R1–4 on freshly 
isolated hHSC (blue) against matched isotype control (grey) from seven donors.
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Expression of TRAIL-R4 regulates apoptosis of activated hHSC. Having observed considerable 
variability in the baseline levels of TRAIL-R2, TRAIL-R3 and TRAIL-R4 on hHSC both ex vivo and after acti-
vation, we postulated that receptor expression levels may dictate susceptibility to TRAIL-mediated apoptosis. 
To assess this, we compared the expression of TRAIL-R2, TRAIL-R3 and TRAIL-R4 (as TRAIL-R1 was unde-
tectable) on activated hHSC isolated from liver tissue from 5 different donors (Fig. 5a). Receptor expression 
levels were then compared with the susceptibility to TRAIL-induced apoptosis of the individual batches of hHSC 
(Fig. 5b). The level of TRAIL-R2 and TRAIL-R3 did not correlate with induced apoptosis (r = −0.3 P = 0.68 
and r = 0.6 P = 0.35 respectively), whereas TRAIL-R4 expression showed a robust inverse correlation with the 
induction of caspase-3 cleavage in hHSC treated with SuperKiller TRAIL (r = −1 p = 0.017, Fig. 5c). This finding 
suggested that TRAIL-R4 is a critical physiological regulator of hHSC apoptosis.
Figure 3. Impact of knockdown of TRAIL-R3/4 on hHSC susceptibility to TRAIL-mediated killing. (a) 
Percentage expression of TRAIL-R3 (left graph) and (b) TRAIL-R4 (right graph) on activated hHSC (filled 
symbols) and LX2 (open symbols) following lentiviral vector transduction with shRNA against TRAIL-R3 or 
TRAIL-R4 (shTR-3, shTR-4) compared to control short hairpin (shCTR). (c) and (d) FACS plots and summary 
data of induction of apoptosis (caspase3+) by SuperKiller TRAIL treatment of hHSC transduced with shCTR 
and shTR-3, shTR-4. Baseline levels of caspase-3 post-transduction without addition of SuperKiller TRAIL are 
subtracted.
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Discussion
In order to develop new approaches for the treatment of liver fibrosis, it is essential to gain a better understand-
ing of the factors that can terminate its progression and/or mediate its resolution. A central feature of fibrosis 
regression is the apoptosis of activated HSC, which is known to be a tightly regulated process3–5. A previous study 
has shown that high levels of the anti-apoptotic protein Bcl-2 in activated hHSC can limit their susceptibility to 
apoptotic stimuli through the cell-intrinsic pathway32. Here we demonstrate a novel mechanism of resistance to 
cell-extrinsic apoptosis, through variable expression of regulatory receptors for the death ligand TRAIL.
Since the original cloning of the TRAIL-R3 and TRAIL-R4 receptors in 199718, 22–25, there has been debate over 
their mode of action and limited evidence for a physiological role. Their lack of an intracellular death domain 
led to the concept that they may act as classical decoy receptors, binding to TRAIL and limiting its engagement 
of the death-domain-containing receptors TRAIL-R1 and TRAIL-R228, 30, 31. In support of this concept, recent 
evidence suggests TRAIL-R3/4 may be able to act in both cis and trans, sequestering TRAIL to inhibit killing 
of neighbouring cells as well as exerting a cell-autonomous effect33. Conversely, another study has shown that 
TRAIL-R4 can inhibit TRAIL-R2 in a non-ligand-dependent manner, involving the formation of TRAIL-R2/4 
heterocomplexes34. Some have argued that the regulation of TRAIL-induced apoptosis of non-transformed cells 
is controlled at the level of downstream mediators including c-FLIP, XIAP and Mcl-1 rather than the surface 
expression of TRAIL-R3/428, 35, 36. Apoptosis regulation mediated by physiological levels of TRAIL-R4 on primary 
cells has only been demonstrated once, for mitogen-activated T cells34 and no physiological inhibitory role for 
TRAIL-R3 or the combination has been shown before.
Using flow cytometry we were able to show expression of TRAIL-R3 and TRAIL-R4 on both freshly isolated 
and culture-activated hHSC. This is in line with the recent identification of these inhibitory receptors on stromal 
cells within tumour tissue33. Importantly, our findings revealed novel non-redundant functional roles for both 
TRAIL-R3 and TRAIL-R4. The fact that shRNA-mediated knockdown of TRAIL-R3/4 was able to sensitise hHSC 
to apoptosis implied that these receptors can act as primary inhibitors, although it did not exclude additional 
downstream regulation by mediators such as cFLIP. The pivotal role of TRAIL regulatory receptors in this set-
ting was underscored by the striking correlation between the levels of TRAIL-R4 expressed by hHSC isolated 
from different livers and their susceptibility to apoptosis induction. Our finding that blockade of TRAIL-R3/4 also 
enhanced the capacity of NK cells from a number of donors to kill hHSC illustrated that these receptors can exert 
inhibition of cell-bound TRAIL, even in a setting where there is the potential for it to be overridden by alternative 
NK cell killing pathways.
Figure 4. Blocking TRAIL-R3/4 on hHSC increases their susceptibility to NK cell mediated apoptosis. (a) 
FACS plots of induction of apoptosis (caspase3+) in hHSC co-cultured with NK cells from patients with 
hepatitis B with or without TRAIL-R3 or TRAIL-R4 blockade. (b) Percentage apoptosis of hHSC with an 
isotype blocking mAb (white) or with mAb blocking TRAIL-R3 (αTR3, blue), TRAIL-R4 (αTR4, red) or 
combination of αTR3 and αTR4 (green bars) upon NK cell co-culture. Responders whose NK cells induced 
>5% more apoptosis of hHSC with one or more strategy are shown, with %caspase3 induction normalised to 
the positive control (SuperKiller TRAIL) to adjust for inter-donor hHSC variability.
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Our data highlight the need for further studies to fully elucidate the contribution of TRAIL receptors in 
determining the lifespan of hHSC and resultant progression versus resolution of liver fibrosis. The capacity we 
observed of TRAIL-R4, in particular, to calibrate activated hHSC apoptosis in vitro suggests it may have merit 
as a biomarker of the potential for fibrosis progression versus regression. It would be interesting to see whether 
histological assessment of the balance of expression of death-inducing TRAIL-R2 versus inhibitory TRAIL-R3/4 
on hHSC in biopsy tissue from patients with hepatitis B or other liver diseases can serve as a personalised pre-
dictor of fibrosis progression. Emerging data emphasise that TRAIL-R2 and TRAIL-R4, in addition to being 
apoptosis-regulating receptors, have the capacity to drive a pro-inflammatory/pro-proliferative state by activation 
Figure 5. Relationship between expression levels of TRAIL-receptors and resistance to TRAIL-mediated 
apoptosis. (a) Expression levels of TRAIL-R2 (top panel), TRAIL-R3 (middle panel) and TRAIL-R4 (bottom 
panel) in blue against matched isotype (grey) on in vitro culture-activated hHSC from five different donors 
(hHSC1–5). (b) Levels of induction of caspase-3 in hHSC at baseline and on in vitro treatment with SuperKiller 
TRAIL. (c) Correlation of expression levels TRAIL-R4 on hHSC against their capacity to undergo TRAIL-
mediated apoptosis.
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of NFkB-dependent genes22, 27, 37, 38; the possibility that these receptors may therefore actively potentiate liver 
fibrosis (in addition to limiting its resolution) should therefore be investigated.
Our results also have therapeutic implications. In hepatitis B, we have previously proposed the use of TRAIL 
blockade as an adjunct to therapeutic vaccination because of its potential to prevent NK cell-mediated deletion 
of TRAIL-R2-bearing antiviral T cells and hepatocytes and thereby favourably shift the balance of immunity and 
immunopathology39. A concern has been the risk of accelerating liver fibrosis by preventing clearance of activated 
hHSC by endogenous TRAIL-expressing NK cells; our new data suggest that short-term TRAIL blockade may 
not have a detrimental effect in patients whose regulatory receptors are already limiting stellate cell apoptosis. 
Conversely, TRAIL is being considered as an anti-fibrotic therapy in other causes of progressive liver fibrosis due 
to ongoing liver injury. A recent study showed promising effects of a pegylated form of TRAIL in ameliorating 
liver cirrhosis by eliminating activated HSC in a rodent model of liver fibrosis26. Our findings imply that engage-
ment of TRAIL-R2 without TRAIL-R3/4 would optimise stellate cell killing and the regression of fibrosis. This 
could be achieved, for example, with TRAIL receptor agonists which have recently been engineered to bind only 
to TRAIL death-inducing receptors and are unable to engage the inhibitory TRAIL-R3/433, 40. Such an approach is 
supported by the superior efficacy of a TRAIL-R2 targeted ligand over native TRAIL in eliminating LX-2 or acti-
vated rat stellate cells in vitro40; further studies are needed to see if such reagents achieve the predicted enhanced 
clearance of human HSC.
Patients and Methods
All experiments were performed in accordance with the approved guidelines and regulations.
Patient samples. Ethical board approval for the study was submitted through the Royal London Hospital 
and Royal Free London NHS Foundation Trust. All participants of the study have given written, informed con-
sent. All HBV infected patients were anti-HCV and anti-HIV antibody negative. The patients were stratified on 
the basis of their disease status (Table 1): viral load (determined by real-time PCR), liver inflammation indicated 
by serum levels of alanine transaminase (ALT) and degree of fibrosis determined by Ishak stage and/or ELF 
test (Ishak stage: 1–2 mild fibrosis, 3–4 moderate fibrosis; ELF test: 0–7.7 no/mild fibrosis, 7.7–9.8 moderate to 
severe fibrosis). For the isolation of primary human HSC, liver tissue was obtained from healthy margins of livers 
resected for colorectal cancer metastases.
Isolation of hHSC. Liver tissue was digested using enzymes (1ng/ml of collagenase IV and 0.1ng/ml of 
DNAse I) and mechanical mashing. Optiprep (Sigma-Aldrich, St Louis, USA) double density gradient (17% and 
11.5%) was used to isolate the top layer of retinoid-rich hHSC41. The cells were either stained directly ex vivo 
(identity confirmed by autoflourescence and flow cytometric exclusion of other liver cells) or expanded and acti-
vated by culture on plastic in SteCM media (ScienCell Research Laboratories, California, USA) as described 
previously42 before being cryopreserved for future experimental use. All hHSC were used for experimental assays 
between passage 2 and passage 5. The immortalised human HSC cell line LX2, kindly provided by S. Friedman, 
was cultured in SteCM media and used for experimental assays at passage 2, at a maximum confluency of 80%.
Isolation of NK cells. NK cells were isolated from whole PBMC by negative selection using an NK cell isola-
tion kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. The purity 
of NK cells was checked using flow cytometry by gating on live CD56 + CD3- cells and was always greater than 95%.
Apoptosis assay. Cryopreserved hHSC were thawed and cultured in T-25 tissue culture flasks (NUNC, 
Waltham, USA) for 4 days at 37 °C with 5% CO2. The hHSC were then detached using 0.05% Trypsin/EDTA 
(Invitrogen, California, USA) and plated on 48 well plates (Corning, New York, USA). Where LX2 were used in 
assays, they were treated the same way as pHSC.
Isolated NK cells and hHSC were co-cultured at an E:T ratio of 10:1 for 5 hours in SteCM. After co-incubation, 
hHSC were harvested and their apoptosis was studied by intracellular staining for active caspase-3 using an active 
caspase-3 apoptosis kit (BD Bioscience, Oxford, UK) according to manufacturer’s instructions. The data were 
collected on BDTM LSR II flow cytometer (Beckton Dickinson, New Jersey, USA) and analysed using FlowJo 
(Treestar, Oregon, USA). The positive control for apoptosis experiments was 500 ng/ml of SuperKiller TRAIL 
(Enzo Lifesciences, Exeter, UK). For these NK-hHSC apoptosis assays, the data has been represented as percentage 
of caspase 3 normalised to positive control (Fig. 4b, Supplementary Figure 2B). This is done by using the positive 
control to reflect the maximum (100%) potential of the HSC to undergo apoptosis in each individual experiment, 
the cleaved caspase 3 levels of HSC at baseline and post co-culture with NK cells are calculated in relation to pos-
itive control. This normalisation was done to account for inter-donor variability of hHSC to undergo apoptosis.
Age in years 
median (range)
Sex 
(female:male) HBeAg+
HBV DNA IU/ml 
median (range)
ALT IU/L 
median (range)
Fibrosis (severe/
moderate:mild/no)
CHB patients 
(n = 59) 36 (19–60) 23:26 7/52
1,667 (not detected 
–100 × 106) 49 (10–748) 43.9:56.09
Healthy Controls 
(n = 20) 31 (21–35) 9:11 NA NA NA NA
Table 1. Clinical characteristics of CHB patients and healthy controls.
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Real-time qPCR. Total cellular RNA was extracted using QIAzol Lysis Reagent and RNeasy Mini Kit 
(Qiagen, CA, USA) according to the manufacturer’s protocol. After RNA quantification and quality control using 
NanoDrop1000 System (Thermo Scientific, USA), cDNA was synthesized with MultiScribe reverse transcriptase, 
random primers, deoxyribose nucleoside triphosphate (dNTP) mix and RNase inhibitor (all Applied Biosystems, 
CA, USA) according to the following protocol: 2 min 50 °C, 10 min 95 °C, followed by 40 cycles of 15 seconds 
95 °C and 60 seconds 60 °C.
6.25 ng of the cDNA sample was used to set up real-time quantitative PCRs reactions using TaqMan® gene 
expression assays Hs00366278_m1 TNFRSF10B and Hs02758991_g1 GAPDH (Life technologies, CA, USA) and 
7500 Fast Real-Time PCR System following the manufacturer’s protocol. Each sample was tested in duplicate. To 
quantify gene expression, the comparative CT method was used as described previously43 using Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as the internal control. The amplification efficiency of target and reference 
genes was approximately the same (slope < 0.1).
Blocking TRAIL-R3/4. TRAIL-R3 (MAB-630, R & D Systems, Minneapolis, USA) and TRAIL-R4 (MAB-633, 
R & D Systems, Minneapolis, USA) neutralizing monoclonal antibodies (mAb) were used to block these recep-
tors on pHSC. The antibodies were added at a concentration of 5 µg/ml for 30 minutes to HSC cultures. Matched 
isotypes of these were used as controls. The neutralizing antibodies were washed off using PBS prior to setting up 
apoptosis assays.
Surface staining of HSC and NK cells. Freshly isolated hHSC were stained with mAbs against 
CD19-APC-Cy7, CD146-FITC (BioLegend, London, UK), CD14-v500, CD45-FITC (BD Biosystems, Oxford, 
UK), CD68-FITC, Cytokeratin-FITC, CD3-PE-Cy7 (eBioscience, Hatfield, UK), CD56-ECD (Beckman 
Coulter, High Wycombe, UK), TRAIL-R1-PE, TRAIL-R2-PE, TRAIL-R3-PE and TRAIL-R4-PE (R&D Systems, 
Abingdon, UK) after FcR blocking reagent (Miltenyi Biotec, Surrey, UK) blocking. Appropriate isotype con-
trols were used where necessary. NK cells were stained for CD56-ECD (Beckman Coulter, High Wycombe, 
UK), CD3-PE-Cy7 (eBioscience, Hatfield, UK), CD16-APC, TRAIL-PE. All cells were stained with Live/Dead® 
Cell viability stain (Invitrogen, California, USA). Data were acquired on BDTM LSR II flow cytometer (Beckton 
Dickinson, New Jersey, USA) and analysed using FlowJo (Treestar Oregon, USA).
Transducing HSC using lentiviral vectors with shRNA. The lentivector pSIN-GFP was digested with 
EcoRI and BamHI, and the promoter of the gene encoding phosphoglycerate kinase (PGK) was amplified by pol-
ymerase chain reaction (PCR) for introduction of EcoRI-BamHI restriction sites. The SFFV promoter from the 
plasmid pSIN-GFP was replaced with the promoter of the gene encoding PGK, cloned by blunt-end ligation, to 
generate the plasmid pSIN-PGK-GFP. A second cassette containing the U6 promoter was cloned in this backbone 
downstream the cPPT sequence between ClaI-EcoRI restriction sites. A BamHI site was introduced downstream 
of the U6 promoter to clone the short hairpin RNA (shRNA) of interest between BamHI and EcoRI restriction 
sites. The U6-shRNA cassette was placed upstream the PGK promoter and GFP. All constructs were engineered 
by standard cloning techniques.
The following shRNA sequences were used:
shTR2: 5′-CTCACTGGAATGACCTCCTTTTTCAAGAGAAAAGGAGGTCATTCCAGTGAG-3′
shTR3: 5′-CTTCCAACAATGAACCTTCTTTTCAAGAGAAAGAAGGTTCATTGTTGGAAG-3′
shTR4: 5′-GATGGTCAAGGTCAGTAATTGTTCAAGAGACAATTACTGACCTTGACCATC-3′
shCTR: 5′-CCTAAGGTTAAGTCGCCCTCGTTCAAGAGACGAGGGCGACTTAACCTTAGG-3′
Transduction was monitored by GFP expression using fluorescence microscopy. Lentiviruses were produced 
using a packaging cell line (293T-cells) and transfected with p8.91 (encoding structural proteins, gag, pol, rev, 
tat), pMDG (encoding VSVg env) and transfer vectors pSIN shCTR or pSIN shTR2. The shCTR (shCONTROL), 
shTR4 (shTRAIL-R4), shTR3 (shTRAIL-R3) and shTR2 (shTRAIL-R2) carrying lentivirus were transduced into 
HSC plated in a 48 well plate in 500 μl volume of SteCM at an MOI (multiplicity of infection) of 40 for up to three 
days. Transduction and knockdown was confirmed using FACS.
Statistical analysis. Wilcoxon signed rank test was performed for all paired data. While comparing 
non-paired data, Mann-Whitney U test was performed. For correlation data, Spearman’s r test was used.
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